Skip to content Skip to footer

Clinical Projects

CanceRx LLC
Projects

At CanceRx, we have several projects under review. Those nearing completion of early stage negotiations include:

We are making strategic selections for novel therapies as we scale up our clinical development operations.”

Cody Gibbons, COO, CanceRx

Novel Drug Delivery System, Polymeric Nanoparticles

Pancreatic Cancer

A Phase I Clinical Trial to Evaluate Tolerability and Safety of XXXX-PNP-PEG Infusion for Advanced Pancreatic Carcinoma.
A Phase II Clinical Trial to Evaluate Tolerability and Safety of XXXX -PNP-PEG in Subjects with Early-Stage Pancreatic Cancer.

Leukemia

A Phase I Clinical Trial to Evaluate Safety and Tolerability of XXXX-PNP-PEG infusion in Subjects with Acute Myelogenous Leukemia.
A Phase I/II Clinical Trial of XXXX-PNP-PEG in the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia.

Lymphoma

A Phase I Clinical Trial to Evaluate Safety and Tolerability of XXXX-PNP-PEG infusion in Subjects with Advanced Non-Hodgkin’s Lymphoma.
A Phase I /II Clinical Trial to Evaluate Safety and Tolerability of XXXX-PNP-PEG infusion in Subjects with T-Cell Lymphoma.
A Phase I/ II Clinical Trial of XXXX-PNP-PEG in the Treatment of Relapsed Refractory Follicular Lymphoma.

General Malignancy

A Phase I/ II Clinical Trial of XXXX-PNP-PEG in the Treatment of Advanced Malignant Tumors.
A Phase I/ II Clinical Trial of XXXX-PNP-PEG in the Treatment of Non-Small Cell Lung Cancer.
A Phase I/ II Clinical Trial of XXXX-PNP-PEG in the Treatment of Colorectal Cancer.

Novel Drug Delivery System, Polymeric Viral Vectors

Ovarian Cancer

A Phase I Clinical Trial to Evaluate Tolerability and Safety of XXXX-PVV Infusion in Subjects with Advanced Ovarian Cancer.
A Phase I/II A Clinical Trial to Evaluate Safety, Tolerability and Efficacy of XXXX -PVV Infusion in Subjects with Early-Stage Ovarian Cancer.

Multiple Myeloma

A Phase I Clinical Trial to Evaluate Safety and Tolerability of XXXX-PVV infusion in Subjects with Advanced Multiple Myeloma.

Getting In Touch

We encourage you to reach out with questions about CanceRx.


By submitting this form, you are consenting to receive marketing emails from: CanceRx. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
cancerx_white_transparent-sm

No information contained on this website should be construed as a forward-looking statement.

CanceRx Foundation, Inc., is an IRS approved tax-exempt public charitable foundation under Sec. 501(c)(3) of the U.S. Internal Revenue Code.

CanceRx® is a registered trademark.

To learn more, please call or email:

CanceRx Foundation, Inc.

4830 W Kennedy Blvd, Suite 600
Tampa, FL 33609-2584

Phone: (813) 776-0000

Email: donations@cancerx-foundation.org

CanceRx © 2025. All Rights Reserved.
Go to Top